Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 6.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.71M |
| Shares Out | 4.78M |
| EPS (ttm) | -3.75 |
| PE Ratio | n/a |
| Forward PE | 17.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,756 |
| Open | 1.37 |
| Previous Close | 1.38 |
| Day's Range | 1.33 - 1.37 |
| 52-Week Range | 1.06 - 18.75 |
| Beta | -0.62 |
| Analysts | Sell |
| Price Target | n/a |
| Earnings Date | n/a |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATX...
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
MIAMI, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of th...
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI). About Avenue Ther...
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
What In The World Is Going On With Avenue Therapeutics Stock?
Avenue Therapeutics Inc (NASDAQ: ATXI) shares are trading lower by 62.64% to $2.35 Friday morning after the company priced a roughly 3.6 million unit offering at $3.30 per unit.
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
ATXI Stock Alert: What to Know as Avenue Therapeutics Soars 150%
It's been another bumpy day in the stock market, with many stocks opening higher only to lose momentum this afternoon. That said, some companies are outperforming meaningfully today.
What Is Going on With Avenue Therapeutics (ATXI) Stock Today?
Source: Numstocker/Shutterstock.com Avenue Therapeutics (NASDAQ: ATXI) stock is seeing wild movement on Friday following a reverse stock split and regulatory update. Starting with that reverse stock ...
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization o...
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Avenue Therapeutics Stock Trading Halted Today
FDA Advisory Committee to review IV tramadol New Drug Application FDA Advisory Committee to review IV tramadol New Drug Application
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therape...
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today ...
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Option
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today ann...
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Thera...
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
Office of New Drugs concludes that additional input is needed, and U.S. Food and Drug Administration will convene an Advisory Committee meeting Office of New Drugs concludes that additional input is n...
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COV...
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such invest...
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon